Federal Court of Appeal reinterprets product specificity requirements

1 minute read
17 July 2015

Eli Lilly Canada Inc., v Canada (Minister of Health), 2015 FCA 166

On July 17, 2015, the Federal Court of Appeal set aside a judgment of the Federal Court that upheld Health Canada’s refusal to list Canadian Patent 2,379,329 owned by Eli Lilly Canada Inc. on the Patent Register maintained under the PM(NOC) Regulations.

A key victory for innovators, the decision restores the principle (and prior practice) that allows listing of patents claiming ingredients not specifically named in the product, so long as a match exists between the claims as construed and the approved product.

Eli Lilly Canada Inc. was represented by Gowlings lawyers Jay Zakaib, Jennifer Wilkie and Kelly A. McClellan.

NOT LEGAL ADVICE. Information made available on this website in any form is for information purposes only. It is not, and should not be taken as, legal advice. You should not rely on, or take or fail to take any action based upon this information. Never disregard professional legal advice or delay in seeking legal advice because of something you have read on this website. Gowling WLG professionals will be pleased to discuss resolutions to specific legal concerns you may have.